The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Engineered immune cell therapy to treat malignancies refractory to conventional therapies is
modernizing oncology. Although αβ T cells are time-tested chassis for CAR, potential graft …

Cervical cancer is a leading cause of death among women globally, primarily driven by high-
risk papillomaviruses. However, the effectiveness of chemotherapy is limited, underscoring …

Cancer is the leading cause of death globally and there is a worldwide cancer epidemic.
Immunotherapy has emerged as a promising anticancer therapy. In particular, oncolytic …

In the last years, the tumor microenvironment (TME) has emerged as a promising target for
therapeutic interventions in cancer. Cancer cells are highly dependent on the TME to growth …

Currently, CAR-T cell therapy relies on an individualized manufacturing process in which
patient's own T cells are infused back into patients after being engineered and expanded ex …

Endocrine therapy is considered as an effective strategy for estrogen and progestogen
receptor (ER and PR)-positive breast cancer (BRCA) patients, whereas resistance to these …

Colorectal cancer (CRC) is the third most frequent type of cancer, and the second leading
cause of cancer-related deaths worldwide. Current treatments for patients with CRC do not …

Lymphoma is one of the most frequent hematopoietic tumors in dogs and shares similar
features with human counterparts. MicroRNAs (miRNA, small non-coding RNAs) are pivotal …

Background The tumor microenvironment of solid tumors governs the differentiation of
otherwise non‐immunosuppressive macrophages and gamma delta (γδ) T cells into strong …